Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Food insecurity links to poorer mental and physical health in Tasmania

24

May 2026

Food insecurity links to poorer mental and physical health in Tasmania

Food insecurity among adults in Tasmania was strongly associated with lower diet satisfaction and poorer self-rated mental and physical health, with diet dissatisfaction showing the strongest link. The findings suggest that food insecurity limits not only nutrition, but also food choice, agency, wellbeing, and equitable access to acceptable, affordable, and culturally appropriate diets.

Silica nanoparticles dampen early allergy signals in mouse mast cells

24

May 2026

Silica nanoparticles dampen early allergy signals in mouse mast cells

This in vitro study found that negatively charged SiO2 nanoparticles suppressed antigen-induced degranulation and activation-marker changes in IgE-sensitized mouse bone marrow-derived mast cells. By contrast, mTiO2 nanoparticles showed cytotoxic and pro-inflammatory effects, including enhanced DNP-induced IL-6 release, suggesting nanoparticle composition can shape early allergic immune responses.

Scientists reveal why common pancreatic precancer lesions rarely turn deadly

24

May 2026

Scientists reveal why common pancreatic precancer lesions rarely turn deadly

Spatial and single-cell analyses of human donor pancreata showed that PanIN epithelial cells gradually acquire cancer-like molecular features, while their surrounding stromal and immune environment remains closer to normal pancreatic tissue. The findings suggest that delayed or incomplete microenvironmental reprogramming may help explain why most PanIN lesions remain indolent rather than progressing to pancreatic cancer.

CDC report reveals what 24 years of nutrition biomarkers say about America’s health

24

May 2026

CDC report reveals what 24 years of nutrition biomarkers say about America’s health

The 2026 CDC Nutrition Report will make nearly 24 years of NHANES biomarker data easier to use, covering up to 131 nutritional biomarkers in the US population aged 1 year and older. By standardizing blood and urine biomarker trends, demographic patterns, and comparisons of supplement use, the report aims to support nutrition policy, clinical reference intervals, and public health monitoring.

Blood carotenoids offer the clearest signal of fruit and vegetable eating habits

24

May 2026

Blood carotenoids offer the clearest signal of fruit and vegetable eating habits

The review finds that several candidate biomarkers may help estimate fruit and vegetable intake more objectively than self-reported dietary tools, but most remain limited by specificity, sampling burden, supplement use, or incomplete validation. Blood and skin carotenoids appear strongest for habitual intake, while vitamin C, folate, urinary flavonoids, hippuric acid, and potassium may be more useful for short-term intake or intervention adherence.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.